Anti-BCMA-ScFv-4-1BB-CD3ζ (Puro)

$790.00

SKU: LVP1648 Category:

Description

Pre-made Lentivirus express the CAR construct of “3xFLAG-anti-BCMA-ScFV (VL-VH)-CD8 hinge-4-1BB-CD3ζ”. It contains the Puromycin marker allowing the selection of the transduced cells via antibiotic killing.

This CAR construct, contains the N-term 3xFLAG taggedBCMA-scFv [VH-(G4S)x4-VL]” recognition domain, linked to 4-1BB stimulatory domain, expressed under the enhance EF1a promoter. The lentivector’s core structure is represented by the scheme below. 

CAR Lentivector Scheme

BCMA is expressed on the surface of plasma cells, particularly mature B cells, and plays a role in B cell development. BCMA is a target in CAR-T therapy for multiple myeloma. This CAR’s anti-BCMA use the hybrid clone 125 / 171  (Reference).

see details in Product Manual.

4-1BB (CD137) is a surface glycoprotein present on activated T Lymphocytes, CD4+ and CD8+ T cells. It binds to its ligand expressed on antigen-presenting cells (macrophages and activated B cells). It promotes T-cell antitumor activity. 4-1BB is one of the most widely studied co-stimulatory domain used in CAR design.

CD3ζ (T-cell receptor zeta) is expressed by T cells and NK cells. It together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. CD3-zeta is the most commonly used activation component of CARs. It transmits an activation signal to the T cell after the antigen is bound. It can be coupled with additional co-stimulatory signaling for the complete activation.

Negative Controls:  To validate the specificity of the targeted CAR-T killing, you can use the negative control CAR lentivirus: the CAR-ctr1 that has the same lentivector backbone but removed the recognition domain.

Amount: 200 ul/vial at titer of 1×108 IFU/ml, concentrated lentivirus provided in PBS solution, premixed with 10x polybrene (60ug/ml), premade, ready to ship in dry-ice package.

CAT#: LVP1648